Genetic Modeling and Therapeutic Targeting of ETV6-NTRK3 with Loxo-101in Acute Lymphoblastic Leukemia
Kathryn G. Roberts(St. Jude Children's Research Hospital), Charles G. Mullighan(St. Jude Children's Research Hospital), Olga A. Bridges(St. Jude Children's Research Hospital), Brian B. Tuch(Loxo Oncology at Lilly (United States)), Nisha Nanda(Loxo Oncology at Lilly (United States)), Kevin Ebata(Memorial Sloan Kettering Cancer Center), Laura J. Janke(St. Jude Children's Research Hospital)
Cited by 3
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Deletion of <i>IKZF1</i> and Prognosis in Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2009|1.4k
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2014|1.4k